DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVTGet Free Report) in a research note issued on Friday. The firm set a “hold” rating on the stock.

Separately, HC Wainwright dropped their price target on DBV Technologies from $20.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, May 8th.

View Our Latest Stock Analysis on DBVT

DBV Technologies Stock Performance

Shares of DBVT stock opened at $0.57 on Friday. The firm has a market cap of $54.68 million, a P/E ratio of -0.68 and a beta of 0.69. DBV Technologies has a fifty-two week low of $0.42 and a fifty-two week high of $2.26. The business’s 50 day moving average price is $1.26 and its 200-day moving average price is $1.55.

DBV Technologies (NASDAQ:DBVTGet Free Report) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.16. DBV Technologies had a negative return on equity of 56.76% and a negative net margin of 530.89%. The firm had revenue of $1.41 million for the quarter, compared to analyst estimates of $3.20 million. As a group, equities analysts predict that DBV Technologies will post -1.22 EPS for the current year.

Institutional Investors Weigh In On DBV Technologies

Hedge funds have recently made changes to their positions in the company. Cowen AND Company LLC bought a new stake in shares of DBV Technologies during the fourth quarter valued at approximately $49,000. Optiver Holding B.V. boosted its holdings in DBV Technologies by 595.2% in the third quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock worth $374,000 after acquiring an additional 235,337 shares in the last quarter. Finally, Yiheng Capital Management L.P. boosted its holdings in DBV Technologies by 6.2% in the first quarter. Yiheng Capital Management L.P. now owns 5,568,909 shares of the company’s stock worth $4,172,000 after acquiring an additional 327,345 shares in the last quarter. 71.74% of the stock is currently owned by institutional investors.

DBV Technologies Company Profile

(Get Free Report)

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

Featured Stories

Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.